文献速递创伤与烧伤重症综合管理与镇静镇痛

大剂量静脉注射抗坏血酸:已准备好用于创伤性脑损伤的黄金时段?

High-Dose Intravenous Ascorbic Acid: Ready for Prime Time in Traumatic Brain Injury?
PubMed 文献 · Neurocrit Care · 2020-01-01
一句话结论现有临床前及有限临床数据提示,大剂量静脉抗坏血酸可能降低创伤性脑损伤患者的氧化应激和脑水肿,但能否改善临床结局尚待未来临床研究评估。

创伤性脑损伤(TBI)是美国及全球主要公共卫生问题之一,是1至44岁儿童和成人死亡与残疾的首位原因,发病率持续上升。继发性脑损伤发生于初始打击后数小时至数天,是最有效的干预靶点,炎症过程和氧化应激在其病理机制中起重要作用,且因内源性防御机制受损(包括抗氧化剂耗竭)而加剧。抗坏血酸(AA,维生素C)作为还原剂、自由基清除剂和多种生物合成反应的辅因子,在危重病状态下迅速耗竭;大剂量静脉AA在创伤、重症监护、伤口愈合和血液学等多个临床前模型中显示获益,并在脓毒症休克患者中显示与死亡率降低相关。关于大剂量静脉AA对TBI影响的高质量数据缺乏,历史数据在少数患者中显示中枢神经系统病理(尤其TBI)存在急性和严重AA缺乏,且低AA浓度与不良结局强相关;现有临床前数据和有限临床数据提示大剂量静脉AA可能有效降低氧化应激和减少脑水肿,但是否转化为临床结局改善将取决于确定理想目标人群和可能的治疗组合,需在未来临床研究中评估。

要点

  • TBI是1至44岁儿童和成人死亡与残疾的首位原因,继发性脑损伤发生于初始打击后数小时至数天,是最有效的干预靶点。
  • 炎症过程和氧化应激在TBI病理机制中起重要作用,并因内源性防御机制受损(包括抗氧化剂耗竭)而加剧。
  • 历史数据在少数患者中显示中枢神经系统病理(尤其TBI)存在急性和严重AA缺乏,低AA浓度与不良结局强相关。
  • 现有临床前数据和有限临床数据提示大剂量静脉AA可能有效降低氧化应激和减少脑水肿。
  • 大剂量静脉AA能否改善临床结局将取决于确定理想目标人群和可能的治疗组合,需在未来临床研究中评估。

适用人群与场景

  • 创伤性脑损伤(TBI)患者,尤其是初始打击后数小时至数天存在继发性脑损伤风险的早期阶段。

研究设计与关键结果

  • 本文为综述,汇总证据显示:大剂量静脉AA在创伤、重症监护、伤口愈合和血液学等多个临床前模型中显示获益。
  • 大剂量静脉AA在脓毒症休克患者的研究中显示与死亡率降低相关。
  • 历史数据在少数患者中显示中枢神经系统病理(尤其TBI)存在急性和严重AA缺乏,低AA浓度与不良结局强相关。
  • 现有临床前数据和有限临床数据提示大剂量静脉AA可能有效降低氧化应激和减少脑水肿。

证据类型、等级与局限

  • 证据类型:综述。
  • 关于大剂量静脉AA对TBI影响的高质量数据缺乏。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 作者认为,大剂量静脉AA具有极好的安全性和低成本,已准备好用于TBI患者的早期治疗评估,以减轻继发性脑损伤并改善结局。
  • 作者认为,大剂量静脉AA能否转化为临床结局改善将取决于确定理想目标人群和可能的治疗组合,这些因素需在未来临床研究中评估。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

Traumatic brain injury (TBI) is one of the leading public health problems in the USA and worldwide. It is the number one cause of death and disability in children and adults between ages 1-44. Despite efforts to prevent TBIs, the incidence continues to rise. Secondary brain injury occurs in the first hours and days after the initial impact and is the most effective target for intervention. Inflammatory processes and oxidative stress play an important role in the pathomechanism of TBI and are exacerbated by impaired endogenous defense mechanisms, including depletion of antioxidants. As a reducing agent, free radical scavenger, and co-factor in numerous biosynthetic reactions, ascorbic acid (AA, vitamin C) is an essential nutrient that rapidly becomes depleted in states of critical illness. The administration of high-dose intravenous (IV) AA has demonstrated benefits in numerous preclinical models in the areas of trauma, critical care, wound healing, and hematology. A safe and inexpensive treatment, high-dose IV AA administration gained recent attention in studies demonstrating an associated mortality reduction in septic shock patients. High-quality data on the effects of high-dose IV AA on TBI are lacking. Historic data in a small number of patients demonstrate acute and profound AA deficiency in patients with central nervous system pathology, particularly TBI, and a strong correlation between low AA concentrations and poor outcomes. While replenishing deficient AA stores in TBI patients should improve the brain's ability to tolerate oxidative stress, high-dose IV AA may prove an effective strategy to prevent or mitigate secondary brain injury due to its ability to impede lipid peroxidation, scavenge reactive oxygen species, suppress inflammatory mediators, stabilize the endothelium, and reduce brain edema. The existing preclinical data and limited clinical data suggest that high-dose IV AA may be effective in lowering oxidative stress and decreasing cerebral edema. Whether this translates into improved clinical outcomes will depend on identifying the ideal target patient population and possible treatment combinations, factors that need to be evaluated in future clinical studies. With its excellent safety profile and low cost, high-dose IV AA is ready to be evaluated in the early treatment of TBI patients to mitigate secondary brain injury and improve outcomes.

来源:Neurocrit Care,查看原文。版权归原作者所有。

参考来源

  1. Leichtle SW, Sarma AK, Strein M, et al. High-Dose Intravenous Ascorbic Acid: Ready for Prime Time in Traumatic Brain Injury? Neurocrit Care. 2020. PMID: 31440996. doi:10.1007/s12028-019-00829-x

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。